Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pleural Effusion 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lung Neoplasms 1Advanced Solid Tumors 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Cdc25C phosphatase (211-221) × Clear all
NCT04953962 2023-08-15

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

CanBas Co. Ltd.

Phase 2 Completed
36 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00700336 2021-07-20

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

CanBas Co. Ltd.

Phase 1/2 Completed
69 enrolled 9 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03113188 2021-03-10

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

CanBas Co. Ltd.

Phase 1 Completed
47 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00942825 2017-05-24

CBP08-02

CanBas Co. Ltd.

Phase 2 Completed
195 enrolled 8 charts
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion

NCT00551512 2017-03-14

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

CanBas Co. Ltd.

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡